Quantification of Human Papillomavirus cell-free DNA from low volume blood plasma samples by digital PCR

Fabian Rosing[1], Matthias Meier[2], Lea Schroeder[1], Simon Laban[2], Thomas Hoffmann[2], Andreas Kaufmann[3], Nora Würdemann[4], Oliver Siefert[4], Jens Peter Klußmann[4], Yvonne Alt[1], Daniel Faden[5, 6, 7], Tim Waterboer[1] and Daniela Höfler[1*]

[1] Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
[2] Department of Otorhinolaryngology and Head & Neck Surgery, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, University Medical Center Ulm, Ulm, Germany.
[3] Department of Gynecology, HPV Research Laboratory, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
[4] Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, Cologne, Germany.
[5] Department of Otolaryngology-Head and Neck Surgery, Boston Medical Center, Boston, Massachusetts.
[6] Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts.
[7] Mass Eye and Ear, Boston, Massachusetts.

Abstract

The incidence rate of human papillomavirus-driven oropharyngeal cancer (HPV-OPC) is increasing in many countries with a high human development index. HPV cell-free DNA (cfDNA) has been successfully used for therapy surveillance of HPV-OPC patients. Another currently highly discussed application is early detection of HPV-OPC where particularly sensitive and specific cfDNA detection methods are needed. To study pre-diagnostic cfDNA, archived biobank samples with very limited plasma volume could be highly informative.

To establish a cfDNA detection workflow optimized for low plasma volumes we compared two cfDNA purification methods (MagNA Pure 96 and QIAamp ccfDNA/RNA) and two digital PCR systems (Biorad QX200 and QIAGEN QIAcuity One) and used 65 plasma samples from OPC patients with pre-defined HPV status (34 HPV16+, 1 HPV33+, 2 HPV58+, 28 HPV-) for validation.

The MagNA Pure 96 yielded a 28% higher cfDNA isolation efficiency in comparison to the QIAamp ccfDNA/RNA kit. Both digital PCR systems showed comparable analytical sensitivity (detection limits 6 - 17 copies for HPV16 and HPV33), but the increased multiplexing

capacity gives the QIAcuity an advantage over the QX200. In the validation set, the assay had a sensitivity of 80% (28/35) for detecting HPV16 and HPV33, and a specificity of 97% (29/30). In samples with ≥750 µl plasma available, the sensitivity was 85% (17/20), while in samples with ≤500 µl plasma the sensitivity was 73% (11/15).

Despite the expected drop in sensitivity with decreased plasma volume, the assay is sensitive and highly specific even in the low volume samples, and thus could be used for studies exploring HPV cfDNA as an early HPV-OPC detection marker in low volume archival material.

Keywords

HPV, liquid biopsy, digital PCR, OPC, cfDNA, early detection

1. Introduction

Infection with high-risk human papillomavirus (HPV) is one of the leading causes of cancer worldwide, accounting for 5 % of all cases [1]. HPV is a sexually transmitted infection and is therefore primarily associated with cancers of ano-genital sites, such as vulvar, penile, and anal carcinomas, and particularly with more than 99% of all cervical carcinoma cases [1], but also cancer at other sites, such as oropharyngeal cancer (OPC) [2]. Due to a strong increase of HPV-driven OPC, in some countries with a high human development index, OPC is now the most frequent HPV-driven cancer [2]. HPV-driven OPC mostly arises from the epithelium of the tonsillar crypts and the base of tongue and is often diagnosed at a late stage after regional spread to nearby lymph nodes, making extensive treatment necessary [3]. The clinical standard for determining the HPV status of OPC is p16-immunohistochemistry (p16-IHC) [4], usually accompanied by some form of HPV DNA detection, often by PCR. Despite the overall good prognosis of HPV-driven OPC, survivors often experience serious morbidity after treatment, with one of the common long-term side effects being dysphagia, often necessitating the permanent use of a percutaneous gastrostomy tube [5]. Early detection of OPC may decrease the need for extensive treatment, possibly leading to an improved quality of life. This is complicated by the fact that, contrary to cervical carcinoma, no precancerous lesions of OPC are known to date [6]. Therefore, screening and early detection (also referred to as secondary prevention) are currently not feasible. Primary prevention, mainly HPV vaccination, is highly effective at preventing cervical cancer and, most likely, HPV-driven OPC as well, as the vaccine reduces the prevalence of oral high-risk HPV infection [7]. However, due to OPC mainly affecting males, and the low uptake in males, HPV vaccination is not expected to have an impact on HPV-OPC incidence rate for decades to come. Hence, HPV-driven OPC incidence rates are projected to keep increasing until at least the mid-2030s [8].

While cells undergo apoptosis or necrosis they shed DNA into their environment [9]. In blood plasma, this DNA is also called circulating cell-free DNA (cfDNA). In healthy individuals it is mostly derived from hematopoietic cells [10], but in cancer patients a significant fraction of it can be derived from the tumor. In cancer patients the proportion of tumor-derived cfDNA varies from less than 5 to more than 90% [9]. cfDNA concentrations can vary widely between patients, with typical values spanning from 10 to 1200 ng/ml [9]. As cfDNA is often of very low abundance and highly fragmented, with a typical fragment size of ~ 180 bp [9], specialized protocols and assays are necessary for its analysis. Detection of HPV cfDNA in blood plasma can identify OPC patients with high sensitivity and specificity [11] and has been successfully used for diagnosis, prediction of recurrence, and monitoring

therapy response in OPC [12] [13] [14]. HPV cfDNA presence after intended curative treatment is a highly specific predictor of recurrence, and recurrence has been detected up to 166 days earlier by HPV cfDNA in comparison to standard imaging techniques[15]. Therefore, HPV cfDNA is a promising candidate biomarker for a screening approach due to being minimally invasive and a highly sensitive and specific [16] biomarker for HPV-driven malignancies. Currently the standard method for analyzing cfDNA is digital droplet PCR (ddPCR). The method relies on partitioning the PCR into many thousand partitions, usually by generating droplets in an emulsion (for instance BioRad QX200), but nanoplate-based approaches exist as well, such as the QIAGEN QIAcuity, then referred to as digital PCR (dPCR).The market for ddPCR devices has been rapidly evolving, with new devices being capable of detecting multiple targets at once. While the vast majority of HPV-OPC are caused by HPV16, there is rising interest in detection of other HPV-types as well, especially in relatively high-incidence countries [14]. In plasma samples at OPC diagnosis the sensitivity of ddPCR has been reported to range from 70% [17] up to more than 98% [14]. ddPCR is more sensitive than qPCR in HPV16-cfDNA detection from OPC [17] and comes with lower cost per sample than sequencing based approaches, even though the latter has been reported to reach even higher sensitivity than ddPCR [17][17]. Due to the fragmented nature of cfDNA, for any PCR-based method it is of high importance to use very small amplicon sizes to maximize sensitivity of the assay in this material. Most studies have focused on application of the method for therapy surveillance or diagnosis, so that often 3 ml or more of plasma are available for analysis [13] [14] [18]. To study the performance of HPV cfDNA as a predictive biomarker of HPV-OPC it will be necessary to analyze existing samples from biobanks, where often only small amounts of plasma are available.

Antibodies against high-risk HPV E6 oncoprotein are strongly associated with HPV-driven cancer at diagnosis [19] and have been shown to be also highly specific and sensitive pre-diagnostic biomarkers of OPC [20]. Seroconversion has been observed to occur at any time point from 6 up to 28 years before onset of disease [21]. These antibody patterns have been successfully used to identify individuals at risk for development of OPC in a prospective manner before onset of symptoms [22] [23]. As currently no pre-cancerous lesions in the oropharynx are known, repeated in-depth exams by otorhinolaryngologists over a long period of time are necessary for early detection of OPC, putting a considerable burden on both the patients and the healthcare system. Therefore, additional minimally invasive biomarkers for OPC are necessary which are indicative of onset of disease within a shorter timeframe than HPV16 E6 serology, in order to correctly identify the people at highest risk of developing HPV-OPC in a timely manner to minimize anxiety and unnecessary medical exams. HPV-cfDNA could hold the potential to complement serology in this approach.

119 The aim of this study was to establish an optimized protocol for the purification and
120 quantification of HPV-cfDNA from small volumes of blood plasma. While nucleic acid
121 purification efficiency is usually not a key determinant of cfDNA detection when the
122 standard 4 ml of blood plasma are available in a clinical setting, it could be of importance
123 when only limited amounts of plasma are available. For this purpose, blood plasma from
124 volunteers was used in the comparison of cfDNA purification methods. To assess the assay
125 analytic sensitivity it was applied to dilution series of the target DNA. In order to rule out
126 non-specific interactions with template DNA from non-target HPV types or human DNA the
127 assay was then tested on DNA from cervical swab samples. For application in liquid biopsies
128 the assay was optimized and test parameters defined based on a test set of 24 OPC patient
129 plasma samples at the point of diagnosis, which was validated in a validation set of 65
130 samples. The initial experiments were performed simultaneously on two different dPCR
131 platforms to compare the methods.

132 2. Material and Methods

133 2.1. **Study participants and samples**

134 Healthy volunteers were recruited in Heidelberg, Germany, and blood draws were
135 conducted by medically trained personnel at the German Cancer Research Center (DKFZ)
136 (Ethical approval S-031/2022, University Heidelberg Ethics Commission). In this study,
137 sodium citrate plasma samples from 86 OPC patients from Ulm University Hospital were
138 used (tbl. 2.1., Ethical approval 90/15 by Ulm University Ethics Commission).

139 Tumor HPV status was determined by p16-IHC [4] and HPV detection by GP5+/6+ PCR [24]
140 and subsequent sequencing of PCR products for HPV typing. Tumor sections were classified
141 as HPV-driven by a pathologist if the sample was both HPV-DNA and p16 IHC positive. p16
142 IHC positivity alone with a negative HPV DNA result was not sufficient for the case to be
143 classified as HPV-driven. Three patients in the validation cohort had one sample at initial
144 diagnosis and one at recurrence with distant metastasis. Inclusion criteria for the study were
145 the diagnosis of a tumor in the oropharynx with complete tumor HPV-DNA and p16-IHC
146 data. Samples were assigned to the test and validation set by an independent collaborator
147 not directly involved in the experiments. The two sets did not differ significantly when
148 examining tumor stage, node stage or any other relevant characteristic (tbl. 2.1). The person
149 responsible for conducting dPCR experiments and data analysis was blinded to the tumor
150 HPV status associated with each sample until after the experiment was completed. Available
151 plasma volumes from the first 24 OPC patients (12 HPV16-driven, 2 HPV33-driven, 10 HPV-
152 negative) in the test set ranged from 0.38 to 2.9 ml (mean volume of 1.14 ml). The samples
153 were collected between 2013 and 2020 (mean storage time since blood draw 5.5 years). In

154 the validation set of 65 plasma samples from 62 HPV-OPC patients (33 HPV16-driven, 2
155 HPV58-driven, 1 HPV33-driven, 26 HPV-negative) available plasma volumes varied between
156 0.37 and 3 ml (mean volume of 1.01 ml).

157 **Table 2.1: Patient characteristics compared between the test and validation set.**

Characteristic	**Test set**, N = 24	**Validation set**, N = 62	**p-value**
HPV type			0.38[1]
16	12 (50%)	33 (53%)	
33	2 (8.3%)	1 (1.6%)	
58	0 (0%)	2 (3.2%)	
HR[2] HPV negative	10 (42%)	26 (42%)	
p16			0.89[1]
1	14 (58%)	39 (63%)	
0	10 (42%)	23 (37%)	
Age at diagnosis[3]	58 (54, 63)	61 (56, 67)[4]	0.13[5]
Sex			0.24[1]
male	21 (88%)	45 (73%)	
female	3 (13%)	17 (27%)	
OPC subsite			0.24[1]
tonsil	14 (58%)	48 (77%)	
base of tongue	9 (38%)	11 (18%)	
soft palate	1 (4.2%)	2 (3.2%)	
lateral pharyngeal wall	0 (0%)	1 (1.6%)	
T stage			0.81[1]
T1/2	13 (54%)	32 (52%)	
T3/4	11 (46%)	29 (47%)	
Unknown	0 (0%)	1 (1.6%)	
N stage			0.56[1]
N0/1	15 (63%)	44 (71%)	
N2/3	9 (38%)	17 (27%)	
Unknown	0 (0%)	1 (1.6%)	
Stage			0.77[1]
Stage 1/2	14 (58%)	39 (63%)	
Stage 3/4ab	10 (42%)	21 (34%)	
Stage 4/4c	0 (0%)	1 (1.6%)	
Unknown	0 (0%)	1 (1.6%)	

158 N (%), [1]Pearson's Chi-squared test, [2]HR = high-risk, [3]Median (IQR), [4]Age missing for one
159 patient,[5]Kruskal-Wallis rank sum test

160 2.2. **Plasma sample collection**

161 Anonymized blood samples from healthy volunteers were processed within 1 h after
162 collection by centrifugation at 600 x g for 10 minutes. The plasma phase was centrifuged
163 again at 1200 x g for 10 minutes. The resulting plasma was split into 1 ml aliquots and stored
164 at -80°C. For each experiment, a minimum of 5 plasma sample aliquots were pooled and
165 thoroughly mixed before proceeding.

166 2.3. **cfDNA isolation and purification efficiency assessment**

167 Before nucleic acid isolation, plasma samples were equilibrated to room temperature and
168 centrifuged at 3000 x g for 5 minutes. Automated cfDNA purification was performed using
169 the *DNA and Viral NA Large Volume* kit for the MagNA Pure 96 (Roche Diagnostics,
170 Mannheim, Germany). cfDNA was purified from EDTA plasma (from volunteers) using the
171 *cfNA ss 2000* or *cfNA ss 4000* protocol, depending on the available plasma volume, and the
172 *Viral NA Universal 500* or *Viral NA Universal 1000* protocol for sodium citrate plasma (from
173 OPC patients), as recommended by the manufacturer. The sample volume was calculated
174 based on the mass of the sample and then adjusted to the necessary input volume for each
175 protocol adding PBS if the full volume needed for the protocol was not available (e.g. 1500
176 µl plasma plus 500 µl of PBS for the *cfNA ss 2000* protocol), as recommended by the
177 manufacturer. Purified DNA was eluted in 50 µl elution buffer.

178 The isolation efficiency of the MagNA Pure 96 protocols was compared to the *QIAamp*
179 *ccfDNA/RNA* kit (QIAGEN, Hilden, Germany) to identify the ideal protocol for cfDNA isolation
180 in this study. Isolation by the *QIAamp* kit was conducted according to the manufacturer's
181 instructions and 20 µl of RNAse-free water was used in the final elution step. To identify the
182 optimal DNA purification method, HPV16 DNA was spiked into blood plasma from healthy
183 volunteers (spike-in experiments). 10^4 copies of a 104 bp HPV16E6 DNA fragment confirmed
184 on the Agilent Bioanalyzer were added to pooled plasma samples from healthy volunteers
185 immediately prior to cfDNA isolation. The pooled plasma samples were then thoroughly
186 mixed and split to conduct cfDNA isolation and quantification in multiple replicates across
187 the different kits to be compared. For each replicate the same volume of plasma was used,
188 adjusted to the minimum input volume with PBS as described above. As a reference, the
189 original dilution used as a spike-in was added to each QIAcuity dPCR. The quantification of
190 the original spike-in material was used as a reference point when calculating the isolation

191 efficiency. Isolation efficiency was defined as the number of copies detected after
192 purification divided by the number of copies spiked into the plasma before purification.

193 2.4. **Testing HPV type specificity on cervical swab samples**

194 Cervical swabs were collected at a colposcopy clinic in Berlin (MVZ) by Achim Schneider and
195 colleagues [25] and stored in PreservCyt buffer at 4°C. Samples used were HPV negative
196 (n=21) or positive for HPV16 (n=20), HPV33 (n=11), HPV16 and HPV 33 (n=2), HPV58 (n=8),
197 HPV31 (n=19), HPV35 (n=2), and HPV52 (n=9) as determined by multiplex genotyping (MPG)
198 assay [26]. Samples were vortexed vigorously for 20 seconds, then 250 µl of sample was
199 used for DNA purification. PBS was used to adjust the volume to the required input volume
200 of the kit used. DNA was isolated using the MagNA Pure 96 *Pathogen Universal 500*
201 protocol, eluting in 50 µl of elution buffer. 1 µl of the eluate was used for PCR.

202 2.5. **DNA quantification by dPCR and ddPCR**

203 Isolated DNA was analyzed using both the BioRad QX200 (droplet digital, ddPCR) and the
204 QIAGEN QIAcuity One (digital, dPCR). Both digital PCR assays quantified HPV16 E6 and the
205 human reference gene beta-globin (BG) using specific primers and probes (duplex assay)
206 [27]. On the QIAcuity One, which comes with multiple fluorescence channels to quantify up
207 to five different targets, the assay was complemented by primer-probe sets specific for
208 HPV33 E6 (forward primer: CCAAGCATTGGAGACAACTATAC, probe: TEX-
209 CAACATTGAACTACAGTGCGTGGAATG-BHQ2, reverse primer: AATCATATACCTCAGAT
210 CGTTGC) and HPV16 E7 (forward primer: AAGCAGAACCGGACAGAG, probe: HEX-
211 TGTTGCAAGTGTGACTCTACGCTTCG-BHQ1, reverse primer: TCTACGTGTGTGCTTTGTACG),
212 thus targeting four different targets (four-plex assay). These primers were designed by
213 searching for the most conserved regions in 29 HPV33 E6 and 638 HPV16 E7 sequences
214 available on NCBI GenBank, and searching for sub-sequences with suitable melting
215 temperature (60°C) as calculated by the nearest-neighbour method according to Allawi et
216 al. (1998) [28], a maximum GC content of 70% and minimal self- and cross-compatibility to
217 prevent the formation of primer-dimers. ddPCR on the QX200 system was conducted in 40
218 cycles of 94°C denaturation for 30 seconds and annealing and elongation at 58°C for 1
219 minute. dPCR on the QIAcuity One was conducted in 40 cycles of 95°C denaturation for 10
220 seconds and 60°C annealing and elongation for 30 seconds. For the comparison of the two
221 PCR platforms an input of 10 µl of cfDNA was added per reaction, while in the validation set,
222 where dPCR was run on QIAcuity alone, the volume was 20 µl per reaction. As positive
223 controls and for dilution series plasmids carrying the full HPV16 and HPV33 genomes and BG
224 were used [29,30]. The positive control contained 10^4 copies of HPV16, HPV33 and human

225 BG. Dilution series used had $1.1x10^5$ to 1.9 copies of those templates in 3-fold dilution steps
226 for determining the analytical sensitivity of the assay.

227 2.6. **Statistical analysis**

228 Analysis of the QIAcuity data was conducted using the QIAcuity Software Suite V 2.2. Results
229 exported from the software were further analyzed in R version 4.3.1 [31]. Packages from the
230 tidyverse family of R-packages [32], epiR [33] and caret [34] were used. In the assessment of
231 the analytical sensitivity, the limit of detection (LoD) was defined as the lowest input copy
232 number that yielded a positive result in both duplicates. As in the cervix HPV infection is not
233 uncommon, extremely low viral loads are most likely not informative and also may not have
234 been detected by reference tests. Therefore, in cervical swab samples all samples were only
235 considered HPV-positive if a minimum of 3 partitions was positive for any target. As in blood
236 plasma samples no HPV DNA is expected, in the test set of plasma samples any sample with
237 any positive partitions was classified as HPV-positive. In the validation set of palsma
238 samples, cfDNA samples were only classified as HPV-positive when both replicates were HPV
239 cfDNA-positive. Clinical sensitivity was defined as the number of samples from patients with
240 HPV-driven tumors that had detectable HPV cfDNA divided by the number of all patients
241 with HPV-driven tumors. Clinical specificity was defined as the number of samples from
242 HPV-negative patients with undetectable HPV cfDNA divided by the number of HPV-
243 negative patients. Confidence intervals (CI) for sensitivity and specificity is the Clopper-
244 Pearson confidence interval.

245 3. Results

246 3.1. **Comparison of PCR platforms**

247 3.1.1. **Analytic sensitivity and HPV type specificity**

248 Analytical sensitivity of QX200 ddPCR and QIAcuity dPCR were compared by applying a
249 three-fold dilution series of the corresponding template DNA in duplicates. Since the QX200
250 ddPCR assay quantifies BG and HPV16 E6 only, these two targets were used for a direct
251 assay comparison. The QX200 had a LoD of 17 copies for both HPV16 E6 and BG (fig. 3.1A).
252 The QIAcuity (fig. 3.1A and B) had a lower LoD of 6 copies for HPV16 E6, HPV16 E7 and BG,
253 and a LoD of 17 copies for HPV33 E6. Fewer copies were also detectable in some
254 experiments, but were not reproducible between duplicates.

255 To assess the specificity of the assay on both PCR platforms, DNA from 92 cervical swab
256 samples with known HPV infection status was tested. For these samples any sample with 3
257 or more positive partitions was counted as positive for the given target. In the QX200
258 ddPCR, HPV16 E6 was 100% specific (77/77, fig. 3.1C). Sensitivity was 95.5% (21/22

259 detected), based on one false-negative sample that was defined as HPV16 and HPV33
260 positive by the reference method and yielded less than 3 HPV16 positive partitions. In
261 QIAcuity dPCR, HPV16 E6 was also 100% type-specific but 100% sensitive for both HPV16
262 single infections (20/20) and co-infections (2/2) with HPV33 (fig. 3.1C). However, 12 non-
263 HPV16 cases (out of 77) showed one to two partitions positive for HPV16 E6. HPV16 E6
264 quantification by the two methods was highly correlated (Pearson's r = 0.97) and virtually
265 identical (slope of regression model = 0.93).

266 In QIAcuity dPCR, HPV16 E7 and HPV33 E6 was also quantified in the same reaction. HPV16
267 E7 had a sensitivity of 100% for HPV16 single infections (n=20) and double infections with
268 other HPV types (n=2) (fig. 3.1D). Also, HPV33 E6 had a sensitivity of 100% for HPV 33 single
269 infections (n=11) and double infections (n=2). While specificity for HPV16 E7 was 100%, one
270 single infected HPV16 sample was also positive for HPV33, however with only 7 positive
271 partitions, which is the lowest number detected in any sample. Consequently, the specificity
272 of the HPV33 E6 assay was 98.8%. Overall, no HPV DNA was detected in any sample that
273 was previously tested negative for HPV DNA or for HPV types other than HPV16 and HPV33.



274

275 **Figure 3.1: (A) Quantification of a dilution series of HPV16 and BG template DNA by ddPCR**
276 **on a BioRad QX200 system (x-axis) compared to QIAcuity dPCR (y-axis). Values shown are the**
277 **minimum of duplicates. (B) Copy numbers of HPV16 E6 detected by QX200 (y-axis) and**

QIAcuity (x-axis) in cervical swab samples with known HPV status. The red lines indicate the cut-off of 3 copies that was set to distinguish positive and negative samples. The black line is a regression line fitted to the data with the equation y= 0.11 * 0.93x. R=0.97, p<2.2*10^{6}. (C) Quantification of a dilution series of HPV16 and HPV33 by dPCR on a QIAGEN QIAcuity ONE by primers targeting HPV16 E7 and HPV33 E6. Values shown are the mean of duplicates, the shaded area indicates the standard deviation. (D) Copy numbers of HPV16 E7 and HPV33 E6 detected by dPCR on a QIAcuity ONE in cervix samples with known HPV status. The red line indicates the cut-off of 3 copies that was set to distinguish positive and negative samples.

3.1.2. **Pilot experiment – cfDNA analysis in a test set of 24 OPC patients**

24 plasma samples from OPC patients (12 HPV16-driven, 2 HPV33-driven, 10 HPV-negative) were analyzed to compare the QX200 ddPCR targeting HPV16 E6 and BG, and the QIAcuity dPCR targeting HPV16 E6 and BG, and HPV16 E7 and HPV33 E6 in addition. All samples were tested in duplicates.

When tested in ddPCR on the QX200 system, all samples were positive for BG in both replicates with a mean of 6,022 copies/ml detected (371 – 30,678 copies/ml), indicating sufficient DNA amount and quality. In total, 13 out of 24 samples had any positive droplets for HPV16 E6 (3.33 – 8,750 copies/ml, fig. 3.2A). Three of these were false positive with low HPV16 E6 copies (3.33 – 11 copies/ml), yielding a specificity of 75% (9/12, 95% CI: 43 – 95%). Two of these were positive for HPV33 only in tumor tissue. The assay had a sensitivity of 83.3% for HPV16-driven OPC cases (10/12, 95% CI: 52 – 98%). Applying the definition that a sample is only HPV positive when HPV was detected in both replicates, the sensitivity decreased to 58.3% (7/12, 95% CI: 28 – 62%) and specificity increased to 91.7% (11/12, 95% CI: 62 - 100%) (fig. 3.2B). The lowest concentration that was tested reproducibly positive was 11 copies/ml.

When the assay was run with the extended target panel on the QIAcuity One, a mean concentration of 6,235 copies of BG per ml was detected (201 – 55,220 copies/ml), indicating sufficient DNA amount and quality in all samples. The assay had an overall sensitivity of 71% (10/14, 95% CI: 41.9 - 91.6%) for HPV16 (E6 and/or E7) and HPV33, and a specificity of 100% (10/10, 95% CI: 69.2 - 100%) (fig. 3.2C). HPV33E6 had a sensitivity of 100% (2/2, 95% CI: 15.8 - 100%) for HPV33-driven OPC cases and a specificity of 100% (22/22, 95% CI: 91.1 – 100%). HPV16 E6 had a sensitivity of 50% (6/12, 95% CI: 21.1 – 78.9%) and HPV16E7 of 66% (8/12, 95% CI: 34.9 – 90.1%) for HPV16-driven OPC cases. Both HPV16 assays had a specificity of 91.7% due to one false positive result in a sample from an HPV33-driven OPC patient. The positive samples for each of the targets contained a mean of 3,482 copies of HPV16 E6 (21.2 – 22,780 copies/ml), 3,431 copies of HPV16 E7 (10.6 – 28,880 copies/ml) and 42.7 copies of HPV33 E6 (10.6 – 74.8 copies/ml). 6 samples were positive for HPV16 E6 and E7 and two additional samples were positive for HPV16 E7 only, indicating a

315 better performance of the HPV16 E7 assay. The quantification of HPV16 E6 and E7 was
316 highly correlated (Pearson's r > 0.99, fig. 3.3A). Cohen's kappa was 0.476 for HPV16 E6,
317 0.645 for HPV16 E7 and 1.0 for HPV33 E6. In this experiment there was no correlation of
318 HPV16 E7 copy number with BG copy number (Pearson's r = 0.011, fig. 3.3B). There was a
319 weak correlation between the number of BG copies detected and the plasma volume
320 (Pearson's r = 0.221, fig. 3.3C).

321 One plasma sample from a HPV33-driven OPC case reproducibly tested positive for HPV16
322 E6 (2/2 replicates on QIAcuity, 2/2 replicates on QX200) and HPV16 E7 (2/2 replicates on
323 QIAcuity) in addition to HPV33 E6 (2/2 replicates), indicating that this sample is in fact
324 positive for both HPV types.



325

326 **Figure 3.2: dPCR results of 24 patients from the pilot experiment. (A) Copy number of HPV16**
327 **E6 cfDNA by ddPCR on the QX200, showing the mean value of the replicates. (B) Copy**
328 **number of HPV16 E6 cfDNA by ddPCR on the QX200, showing the minimum value of the**
329 **replicates. (C) Copy number of HPV16 E6, HPV16 E7 and HPV33 E6 cfDNA by dPCR on the**
330 **QIAcuity, showing the minimum value of the replicates.**



Figure 3.3: Figure 3: Comparison of (A) HPV16 E6 and HPV16 E7 copies, (B) HPV16 E7 and BG copies and (C) HPV16 E7 copies per µl of reaction mix and the input blood plasma volume based on data from the QIAcuity digital PCR.

3.2. **Optimization of cfDNA purification**

In order to optimally detect even low concentrations of cfDNA in blood plasma, the performance of different nucleic acid purification methods was analyzed. The automated cfNA-protocol for the MagNA Pure 96 robot was compared with a manual QIAamp ccfDNA/RNA kit using plasma from healthy volunteers spiked-in with HPV16 plasmid DNA. To ensure comparability, one plasma pool was split into multiple aliquots of the same volume and tested on both platforms. As quantified by the QIAcuity, mean isolation efficiency was higher using the cfNA-protocol for the MagNA Pure 96 (51%) compared to QIAamp kit (23%) (fig. 3.4A). Similarly, a higher number of BG copies from the native cfDNA were detected in the MagNA Pure 96 extract (median 1,499 copies) compared to the QIAamp extract (median 372 copies) (fig. 3.4B). When using the MagNA Pure 96 system for isolating HPV DNA spiked into healthy EDTA plasma, as few as 10 copies of HPV DNA added to the PCR were detected in 8 of 8 replicates (100% sensitivity) in the subsequent dPCR, while at 5 copies the sensitivity was 75%. When cfDNA was isolated from sodium citrate plasma samples, the MagNA Pure 96 *cfNA ss 2000* protocol yielded fewer copies of BG per ml of plasma in 3 out of 4 of samples than the* Viral NA Universal 500* protocol, despite using the same input volume in both protocols (fig. 3.4C). Consequently, the latter protocol was used for the sodium citrate plasma samples in the validation experiment.



Figure 3.4: Performance of nucleic acid isolation from blood plasma. (A) Recovery rate of 104 bp HPV16 fragment from EDTA plasma by MagNA Pure 96 cfNA ss 2000 protocol (MP96) or QIAamp ccfDNA/RNA kit (QIAamp). The red triangle indicates the position of the group mean. (B) Number of copies of native BG cfDNA isolated from aliquots of one EDTA plasma pool by MP96 and QIAamp. (C) Comparison of MagNA Pure 96 cfNA ss 2000 protocol and the Viral NA Universal 500 protocol for sodium citrate plasma.

3.3. **Effect of sample volume on quantification**

To gain insight about the effect of the sample volume on sensitivity, aliquots of 500 and 1000 µl were analyzed from 30 plasma samples (15 HPV16+, 2 HPV58+, 13 HPV-negative). The samples were analyzed in duplicates by QIAcuity dPCR, using 20 µl of 50 µl eluate per reaction.

All samples in both of the two groups (500 µl vs. 1000 µl) had sufficient human DNA, as assessed by the reference gene. When 1000 µl of plasma were used for cfDNA isolation, the HPV16 E7 dPCR had a sensitivity of 80% for HPV16-driven tumors (12/15), while HPV16 E6 had 73% (11/15) (fig. 3.5). When 500 µl of sample was analyzed, the assay had a sensitivity of 73% (11/15) for both HPV16 E6 and E7. In total only one HPV-driven OPC case was not detected due to decreased input plasma volume. In total there were two false positive samples, leading to a specificity of the assay of 87% (13/15). In one HPV58+ OPC plasma sample very low amounts (2.5 copies/mL) of HPV16-cfDNA were detected in 500 µl extract only. The other false-positive plasma sample was from an OPC case where the corresponding tumor tissue was HPV DNA-negative but p16-positive, but tested concordantly positive for both HPV16 E6 and E7 cfDNA in both plasma aliquots of 500 and 1000 µl. Overall, the quantification of cfDNA copies per ml was very consistent between the

377 two sample volumes for HPV16 E6 and E7 (r>=0.99), and was comparable for human beta-
378 globin as well (r=0.86).

379



380

381 **Figure 3.5: QIAcuity dPCR result of 30 OPC patient plasma samples (13 negative, 2 HPV58+,**
382 **15 HPV16+), comparing the concentration of each target (in copies/ml plasma) between**
383 **cfDNA isolated from 500 µl (y-axis) and 1000 µl (x-axis) of plasma. (A) HPV16 E7, (B) HPV16**
384 **E6, (C) BG.**

385 ## 3.4. **Validation of final protocol in plasma samples from OPC patients**

386 For the final assessment of clinical sensitivity and specificity the results from the maximum
387 available plasma volume was for a total of 65 plasma samples from OPC patients (34
388 HPV16+, 1 HPV33+, 2 HPV58+, 28 HPV-). In the following analysis HPV58-driven OPC cases
389 were counted as HPV-negative as the assay was not targeted to detect this HPV type. cfDNA
390 was purified from plasma samples by *MagNA Pure 96 Viral NA Universal* protocol and
391 applied in duplicates to QIAcuity dPCR, using 20 µl of 50 µl eluate per reaction. Only samples
392 that tested reproducibly positive for a given target were counted as positive for this target.
393 Sample volumes analyzed for each sample ranged from 370 to 1000 µl (mean of 824 µl). The

394 samples contained a median of 684 copies/ml of human beta-globin (223 – 80,982
395 copies/ml).

396 Samples diagnosed as HPV16 or HPV33-driven by pathology were classified correctly with a
397 sensitivity of 80% (28/35, 95% CI: 63 – 92%, tbl. 3.1), with a specificity of 96.7% (29/30, 95%
398 CI: 83 – 100%). The test had a Cohen's kappa of 0.756, indicating substantial agreement. In
399 samples with 350 – 500 µl of plasma available, the sensitivity of the assay was lower with
400 73.3% (11/15, 95% CI: 45 – 92%), while in samples with 750 – 1000 µl of plasma the
401 sensitivity was 85% (17/20, 95% CI: 62 - 97%). A moderate correlation between the N-stage
402 and the copy number of HPV16 E7 detected in plasma samples from HPV-driven OPCs was
403 observed (R = 0.289), while there was a weak correlation with the T-stage (R = 0.128). There
404 was no correlation between the copy number of human beta-globin detected in the sample
405 and the sensitivity of the assay, but 5 out of 5 cases with more than 10,000 copies of beta-
406 globin were HPV-driven. The age of the sample had no effect on the number of copies of BG
407 detected in the plasma samples (R = -0.076).

408 **Table 3.1: Performance of HPV QIAcuity dPCR of plasma cfDNA in comparison to tumor p16**
409 **status, HPV DNA status and overall HPV status.**

cfDNA[1]	***Tumor Pathology (DNA + p16 IHC)***	
	HPV16 +	**HPV16 -**
HPV16 E7+	27	2
HPV16 E7-	7	29
	HPV16 +	**HPV16 -**
HPV16 E6+	22	2
HPV16 E6-	12	29
	HPV33 +	**HPV33 -**
HPV33 E6+	1	0
HPV33 E6-	0	64
cfDNA[1]	**HPV16/33 +**	**HPV16/33 -**
HPV+[2]	28	1
HPV-[2]	7	29
Sensitivity	0.800	
Specificity	0.967	
Kappa	0.756	

410 [1] HPV detected in plasma by QIAcuity dPCR, [2] HPV+/- summarizes the results of HPV16 E7,
411 HPV16 E6 and HPV33 E6 dPCR; the overall result was positive if any of the three targets was
412 detected in both duplicates for a sample.

413 # 4. Discussion

414 Early detection of OPC holds the potential to improve patient´s quality of life due to early
415 therapeutic intervention requiring less intensive therapy. For this purpose, novel diagnostic
416 molecular biomarkers are needed using minimally invasive protocols. HPV cfDNA is a
417 promising candidate that is successfully being used in therapy surveillance of HPV-driven
418 OPC already. To evaluate this biomarker for early diagnosis a highly sensitive and specific
419 assay is needed that can also be successfully applied to archived material, where usually
420 only small amounts of plasma are available. Here, we describe a digital PCR assay targeting
421 HPV16 and HPV33.

422 To optimize the assay at every step from plasma sample to DNA detection and
423 quantification multiple comparisons of methods were conducted. Due to the superior cfDNA
424 isolation efficiency of the MagNA Pure 96 over the QIAamp kit, the MagNA Pure 96 was
425 used in the final validation set of samples. While the QX200 and QIAcuity showed
426 comparable analytical and clinical sensitivity, the QIAcuity offers higher multiplexing
427 capacity, which enables the targeting of multiple HPV types at once. In addition, the effect
428 of the sample volume on the sensitivity was evaluated. Our results suggest that it is feasible
429 to use lower input volumes than seen in most studies, as using only up to 1 ml of plasma in
430 the validation experiment yielded a sensitivity of 80%, which is comparable to other studies
431 which achieved 70 – 96% sensitivity working with 2 – 4 ml of plasma per sample [13] [15]
432 [18] [17]. Since it has been shown that even in samples with 500 µl or less plasma available
433 the sensitivity is still at 73.3% this allows the use of the assay on samples from large
434 collections in biobanks, where usually only small volumes are available.

435 The increase in sensitivity from the pilot experiment (71%) to the validation set (80%) can be
436 explained by an increased input volume from 10 to 20 µl, due to increased sample volume
437 requirements in the pilot experiment for the comparison of two different dPCR methods,
438 and the use of an optimized cfDNA purification method in the second experiment. The
439 unexpectedly low cfDNA yield in samples with high input volumes prompted a more in-
440 depth comparison of different cfDNA isolation protocols for these samples. This led to the
441 conclusion that the *Viral NA Universal* protocols give a higher yield in these samples than
442 the cfNA protocols, so that the protocol used for cfNA isolation was changed in the second
443 group.

444 The specificity of the QIAcuity dPCR in the final validation set was 96.6%. The one
445 reproducibly false HPV16 E6 and E7 positive sample by dPCR, was HPV DNA-negative, p16-
446 positive by tumor pathology. This could be potentially caused by low HPV copy numbers

447 within the tumor and consequently missed by HPV DNA reference assay. Cross-
448 contamination of the plasma sample by other samples could also be an explanation, which is
449 unlikely as none of the negative controls included in the experiments tested positive for any
450 of the genes targeted. As the plasma sample has been tested positive for antibodies against
451 multiple HPV16 antigens in an independent experiment beforehand using multiplex serology
452 [35] [36] and the tumor tissue being p16-positive, it seems likely that the HPV DNA in the
453 tumor tissue has been missed by the reference assay. Due to the good sensitivity of p16-IHC
454 and the very high specificity of HPV serology [35], it could be reasonably assumed that the
455 tumor was actually HPV-driven, which would set the actual specificity of the assay to 100%.

456 In the pilot experiment and the experiment for the direct comparison of cfDNA isolated
457 from different volumes, three additional false positive cases emerged. In contrast to the
458 HPV DNA result of corresponding tumor tissue samples, additional HPV16 DNA was detected
459 in three plasma samples from HPV33 or HPV58-driven OPC patients. This could be explained
460 by either lack of type-specificity of the assay when applied to cfDNA, which is unlikely as
461 there was no cross-reactivity in cervical swab samples positive for any of these HPV-types,
462 or previously undetected co-infections driving the cancer in these cases due to sensitivity
463 limitations of the reference test. In cervical swabs within this study there were multiple
464 cases of co-infection with these HPV types, which have also been frequently observed in
465 other studies [37], although whether these findings can be transferred to the oropharynx is
466 not clear.

467 Although HPV16 is the most common HPV type among HPV-driven OPC, one limitation of
468 the assay is the small number of HPV types covered. In our study, HPV58 was detect almost
469 as frequently as HPV33. However, only HPV33 was included in the assay due to limited
470 multiplexing spectrum of the dPCR. Since all HPV16 E6 positive sample were also HPV16 E7
471 positive, in future studies the HPV16 E6 can be replaced by primers and probes detecting
472 different HPV types.

473 Since therapy surveillance is a well-established use for HPV cfDNA detection, a more
474 interesting question to answer would be the kinetics of HPV cfDNA before diagnosis of HPV-
475 driven cancer. The possibility of using lower input volumes may open up new sample
476 sources that would not be able to provide the volumes usually used for cfDNA isolation. The
477 assay presented in this study is sensitive and specific even for these smaller input volumes
478 and thus could help exploring the utility of HPV cfDNA in early detection of HPV-driven
479 cancers, which could be feasible due to only requiring minimally invasive sampling.

480 # 5. Conclusions

481 Briefly, we established a novel dPCR detecting HPV16 E6 and E7, HPV33 E6 and the internal
482 BG control on the QIAcuity in low, archived plasma volume after using automated DNA
483 extraction with the MagNA Pure 96. The dPCR was shown to detect sensitively and
484 specifically HPV16 and HPV33. Follow-up studies in larger cohorts are required to explore
485 the use of HPV cfDNA in early detection of HPV-driven OPC.

486 # References

487 [1] Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers.
488 Cancer Biol Med 2020;17:864–78. https://doi.org/10.20892/j.issn.2095-
489 3941.2020.0370.

490 [2] Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated
491 oropharyngeal cancer. Oral Oncol 2014;50:380–6.
492 https://doi.org/10.1016/j.oraloncology.2013.12.019.

493 [3] Hong AM, Martin A, Armstrong BK, Lee CS, Jones D, Chatfield MD, et al. Human
494 papillomavirus modifies the prognostic significance of t stage and possibly n stage in
495 tonsillar cancer. Ann Oncol 2013;24:215–9.
496 https://doi.org/10.1093/annonc/mds205.

497 [4] Mahajan A. Practical issues in the application of p16 immunohistochemistry in
498 diagnostic pathology. Hum Pathol 2016;51:64–74.
499 https://doi.org/10.1016/j.humpath.2015.12.021.

500 [5] You EL, Henry M, Zeitouni AG. Human papillomavirus-associated oropharyngeal
501 cancer: Review of current evidence and management. Curr Oncol 2019;26:119–23.
502 https://doi.org/10.3747/co.26.4819.

503 [6] Franceschi S, Combes JD, Dalstein V, Caudroy S, Clifford G, Gheit T, et al. Deep brush-
504 based cytology in tonsils resected for benign diseases. Int J Cancer 2015;137:2994–9.
505 https://doi.org/10.1002/ijc.29660.

506 [7] Hirth JM, Chang M, Resto VA, Group HPVS. Prevalence of oral human papillomavirus
507 by vaccination status among young adults (18-30years old). Vaccine 2017;35:3446–
508 51. https://doi.org/10.1016/j.vaccine.2017.05.025.

509 [8] Damgacioglu H, Sonawane K, Chhatwal J, Lairson DR, Clifford GM, Giuliano AR, et al.
510 Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal

511 cancer incidence and burden among men in the USA: A modeling study. Lancet Reg
512 Health Am 2022;8:100143. https://doi.org/10.1016/j.lana.2021.100143.

513 [9] Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA
514 fragments in the blood plasma of cancer patients: Quantitations and evidence for
515 their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659–65.

516 [10] Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM. Predominant hematopoietic origin
517 of cell-free DNA in plasma and serum after sex-mismatched bone marrow
518 transplantation. Clin Chem 2002;48:421–7.

519 [11] Nguyen B, Meehan K, Pereira MR, Mirzai B, Lim SH, Leslie C, et al. A comparative
520 study of extracellular vesicle-associated and cell-free DNA and RNA for HPV
521 detection in oropharyngeal squamous cell carcinoma. Sci Rep 2020;10:6083.
522 https://doi.org/10.1038/s41598-020-63180-8.

523 [12] Cao Y, Haring CT, Brummel C, Bhambhani C, Aryal M, Lee C, et al. Early HPV ctDNA
524 kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal
525 squamous cell carcinoma. Clin Cancer Res 2022;28:350–9.
526 https://doi.org/10.1158/1078-0432.CCR-21-2338.

527 [13] Chera BS, Kumar S, Beaty BT, Marron D, Jefferys S, Green R, et al. Rapid clearance
528 profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy
529 correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer
530 Res 2019;25:4682–90. https://doi.org/10.1158/1078-0432.CCR-19-0211.

531 [14] Siravegna G, O'Boyle CJ, Varmeh S, Queenan N, Michel A, Stein J, et al. Cell-free HPV
532 DNA provides an accurate and rapid diagnosis of HPV-associated head and neck
533 cancer. Clin Cancer Res 2022;28:719–27. https://doi.org/10.1158/1078-0432.CCR-
534 21-3151.

535 [15] Haring CT, Bhambhani C, Brummel C, Jewell B, Bellile E, Heft Neal ME, et al. Human
536 papilloma virus circulating tumor DNA assay predicts treatment response in
537 recurrent/metastatic head and neck squamous cell carcinoma. Oncotarget
538 2021;12:1214–29. https://doi.org/10.18632/oncotarget.27992.

539 [16] Tewari SR, D'Souza G, Troy T, Wright H, Struijk L, Waterboer T, et al. Association of
540 plasma circulating tumor HPV DNA with HPV-related oropharynx cancer. JAMA
541 Otolaryngol Head Neck Surg 2022;148:488–9.
542 https://doi.org/10.1001/jamaoto.2022.0159.

543 [17] Mattox AK, D'Souza G, Khan Z, Allen H, Henson S, Seiwert TY, et al. Comparison of
544 next generation sequencing, droplet digital PCR, and quantitative real-time PCR for
545 the earlier detection and quantification of HPV in HPV-positive oropharyngeal
546 cancer. Oral Oncol 2022;128:105805.
547 https://doi.org/10.1016/j.oraloncology.2022.105805.

548 [18] Damerla RR, Lee NY, You D, Soni R, Shah R, Reyngold M, et al. Detection of early
549 human papillomavirus-associated cancers by liquid biopsy. JCO Precis Oncol 2019;3.
550 https://doi.org/10.1200/PO.18.00276.

551 [19] Zumbach K, Kisseljov F, Sacharova O, Shaichaev G, Semjonova L, Pavlova L, et al.
552 Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18
553 in cervical-carcinoma patients from russia. Int J Cancer 2000;85:313–8.
554 https://doi.org/10.1002/(sici)1097-0215(20000201)85:3<313::aid-ijc3>3.0.co;2-w.

555 [20] Holzinger D, Wichmann G, Baboci L, Michel A, Hofler D, Wiesenfarth M, et al.
556 Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for
557 the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int J Cancer
558 2017;140:2748–57. https://doi.org/10.1002/ijc.30697.

559 [21] Kreimer AR, Ferreiro-Iglesias A, Nygard M, Bender N, Schroeder L, Hildesheim A, et
560 al. Timing of HPV16-E6 antibody seroconversion before OPSCC: Findings from the
561 HPVC3 consortium. Ann Oncol 2019;30:1335–43.
562 https://doi.org/10.1093/annonc/mdz138.

563 [22] Waterboer T, Brenner N, Gallagher R, Hillman RJ, Jin F, Grulich A, et al. Early
564 detection of human papillomavirus-driven oropharyngeal cancer using serology from
565 the study of prevention of anal cancer. JAMA Oncol 2020;6:1806–8.
566 https://doi.org/10.1001/jamaoncol.2020.4527.

567 [23] Busch CJ, Hoffmann AS, Viarisio D, Becker BT, Rieckmann T, Betz C, et al. Detection of
568 stage i HPV-driven oropharyngeal cancer in asymptomatic individuals in the hamburg
569 city health study using HPV16 E6 serology - a proof- of-concept study.
570 Eclinicalmedicine 2022;53. https://doi.org/ARTN
571 10165910.1016/j.eclinm.2022.101659.

572 [24] Roda Husman AM de, Walboomers JM, Brule AJ van den, Meijer CJ, Snijders PJ. The
573 use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly
574 conserved sequences improves human papillomavirus detection by PCR. J Gen Virol
575 1995;76 (Pt 4):1057–62. https://doi.org/10.1099/0022-1317-76-4-1057.

576 [25] Hofler D, Bohmer G, Wasielewski R von, Neumann H, Halec G, Holzinger D, et al.
577 HPV16 RNA patterns defined by novel high-throughput RT-qPCR as triage marker in
578 HPV-based cervical cancer precursor screening. Gynecologic Oncology
579 2015;138:676–82. https://doi.org/10.1016/j.ygyno.2015.06.039.

580 [26] Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based
581 multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504–12.
582 https://doi.org/10.1128/JCM.44.2.504-512.2006.

583 [27] Baboci L, Holzinger D, Boscolo-Rizzo P, Tirelli G, Spinato R, Lupato V, et al. Low
584 prevalence of HPV-driven head and neck squamous cell carcinoma in north-east
585 italy. Papillomavirus Res 2016;2:133–40. https://doi.org/10.1016/j.pvr.2016.07.002.

586 [28] Allawi HT, SantaLucia Jr J. Thermodynamics of internal c.t mismatches in DNA.
587 Nucleic Acids Res 1998;26:2694–701. https://doi.org/10.1093/nar/26.11.2694.

588 [29] Beaudenon S, Kremsdorf D, Croissant O, Jablonska S, Wain-Hobson S, Orth G. A novel
589 type of human papillomavirus associated with genital neoplasias. Nature
590 1986;321:246–9. https://doi.org/10.1038/321246a0.

591 [30] Seedorf K, Krammer G, Durst M, Suhai S, Rowekamp WG. Human papillomavirus type
592 16 DNA sequence. Virology 1985;145:181–5. https://doi.org/10.1016/0042-
593 6822(85)90214-4.

594 [31] R-Core-Team. R: A language and environment for statistical computing 2022.

595 [32] Wickham H, Averick M, Bryan J, Chang W, D'Agostino McGowan L, Romain Françoi R,
596 et al. Welcome to the tidyverse. Journal of Open Source Software 2019;4:1686.
597 https://doi.org/10.21105/joss.01686.

598 [33] Stevenson M, Sergeant E. epiR: Tools for the analysis of epidemiological data 2023.

599 [34] Kuhn M. Building predictive models in r using the caret package. Journal of Statistical
600 Software 2008;28:1–26. https://doi.org/10.18637/jss.v028.i05.

601 [35] Hibbert J, Halec G, Baaken D, Waterboer T, Brenner N. Sensitivity and specificity of
602 human papillomavirus (HPV) 16 early antigen serology for HPV-driven oropharyngeal
603 cancer: A systematic literature review and meta-analysis. Cancers (Basel) 2021;13.
604 https://doi.org/10.3390/cancers13123010.

605 [36] Laban S, Gangkofner DS, Holzinger D, Schroeder L, Eichmuller SB, Zornig I, et al.
606 Antibody responses to cancer antigens identify patients with a poor prognosis
607 among HPV-positive and HPV-negative head and neck squamous cell carcinoma

608 patients. Clin Cancer Res 2019;25:7405–12. https://doi.org/10.1158/1078-0432.CCR-
609 19-1490.

610 [37] Kim M, Park NJ, Jeong JY, Park JY. Multiple human papilloma virus (HPV) infections
611 are associated with HSIL and persistent HPV infection status in korean patients.
612 Viruses 2021;13. https://doi.org/10.3390/v13071342.